Pfizer has acquired FoldRx Pharmaceuticals for an undisclosed sum. In doing so, it has gained the rights to tafamidis meglumine, a non-surgical treatment for transthyretin (TTR) amyloid neuropathy (ATTR-PN), a rare genetic disease for which liver transplantation is the only current treatment.